Soft Mist Inhalers Global Market Report 2025

The soft mist inhalers market size has grown strongly in recent years. It will grow from $2.84 billion in 2024 to $3.09 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth during the historic period can be attributed to the increasing prevalence of respiratory diseases, the growing adoption of inhaler devices for asthma and COPD treatment, rising healthcare awareness, growing demand for advanced healthcare solutions, and increasing healthcare expenditure and access.

The soft mist inhalers market size is expected to see strong growth in the next few years. It will grow to $4.24 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth during the forecast period can be attributed to rising global pollution levels, a growing geriatric population, an increasing incidence of asthma and COPD, the rising adoption of non-invasive drug delivery methods, and expanding healthcare infrastructure in emerging markets. Key trends in the forecast period include growing demand for portable and easy-to-use inhalers, a focus on eco-friendly and sustainable inhaler designs, increasing integration of digital health solutions with inhalers, a shift toward personalized and patient-centric treatments, and advancements in drug delivery technology.

The growing prevalence of asthma is expected to drive the expansion of the soft mist inhalers market in the coming years. Asthma is a chronic respiratory disease that leads to inflammation and narrowing of the airways, making breathing difficult. The rise in asthma cases is mainly attributed to the increasing exposure to air pollution, which worsens respiratory conditions and damages lung function over time. Soft mist inhalers assist in managing asthma and other chronic obstructive pulmonary diseases by delivering a fine, slow-moving mist of medication directly to the lungs, improving drug deposition and providing respiratory relief with minimal effort in coordination. For example, in December 2023, the Australian Bureau of Statistics reported that in 2022, about 2.8 million people in Australia (10.8% of the population) had asthma. Additionally, one in three individuals with asthma (33.9%) reported using asthma medication daily. Consequently, the rising prevalence of asthma and chronic obstructive pulmonary disease (COPD) is contributing to the growth of the soft mist inhalers market.

Key players in the soft mist inhalers (SMIs) market are focusing on strategic partnerships to increase their market presence and improve product accessibility. These companies aim to combine their strengths to gain a competitive advantage in delivering innovative, patient-focused inhalation therapies by collaborating with research organizations, technology firms, and local healthcare providers. For instance, in 2024, Merxin Ltd., a UK-based company specializing in the design and supply of generic and customized inhaler devices, formed a partnership with OECHSLERhealth, a German manufacturer of medical devices. This collaboration led to the launch of the Soft Mist Inhalers (SMI) Powerhouse. This initiative aims to speed up market entry for drug developers and includes a partnership with OECHSLER Health to combine its manufacturing and assembly expertise with Merxin’s proprietary SMI design. Together, they plan to set new industry standards in intellectual property protection, performance, reliability, speed, and cost-effectiveness.

In January 2024, Recipharm AB, a Sweden-based pharmaceutical company, joined forces with Medspray to expand the use of soft mist inhaler (SMI) technology beyond conventional respiratory treatments by developing soft mist nasal delivery devices for both single and combination drug products. This partnership aligns with Recipharm’s strategy to innovate drug delivery solutions and diversify its offerings in advanced inhalation technologies. Medspray, based in the Netherlands, specializes in soft mist inhalers and spray delivery systems.

Major players in the soft mist inhalers market are Merck & Co., Novartis International AG, AstraZeneca plc, GlaxoSmithKline plc, Boehringer Ingelheim Pharma GmbH & Co. KG, Philips Respironics Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., 3M Healthcare, Omron Healthcare Inc., AptarGroup Inc., Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals plc, Mundipharma International Limited, Hovione Ltd., Vectura Group Limited, MannKind Corporation, H&T Presspart Ltd., Sunovion Pharmaceuticals Inc., Merxin Ltd., Adherium Limited.

North America was the largest region in the soft mist inhalers market in 2024. The regions covered in soft mist inhalers report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the soft mist inhalers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The soft mist inhalers market consists of sales of respimat inhalers, tiotropium, and ipratropium. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

A soft mist inhaler (SMI) is an inhalation device that delivers medication as a slow-moving, long-lasting aerosol mist, generated without the use of propellants. This method allows for better lung deposition and easier inhalation, making it especially beneficial for patients with limited inspiratory capacity.

The main product types of soft mist inhalers include portable soft mist inhalers and stationary soft mist inhalers. Portable soft mist inhalers are designed for delivering medication in the form of a fine mist for treating respiratory conditions such as asthma or chronic obstructive pulmonary disease (COPD). The various applications of soft mist inhalers include asthma, COPD, and other respiratory diseases. They are used by several end-users, including hospitals and clinics, home care settings, and others.

The soft mist inhalers market research report is one of a series of new reports that provides soft mist inhalers market statistics, including the soft mist inhalers industry global market size, regional shares, competitors with the soft mist inhalers market share, detailed soft mist inhalers market segments, market trends, and opportunities, and any further data you may need to thrive in the soft mist inhalers industry. This soft mist inhalers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.